Immunotherapy

Patients with advanced melanoma who followed the Mediterranean diet tended to have improved responses to immunotherapy treatment, recent research showed.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

The Food and Drug Administration accepted a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.

Patients who do not respond to immunotherapy have reduced CD5 activity in their tumors, opening the door for more effective immunotherapy treatments.

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

Standard corticosteroid use may not be the best treatment for patients with cancer who experience immunotherapy-related heart issues, research showed.

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

A new tool may identify more patients with cancer who can benefit from immunotherapy.

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

Opdivo — even when given in a low dose — was shown to improve outcomes in patients with advanced head and neck squamous cell carcinoma, highlighting a new option for patients who cannot receive the full dose.

As more news is released about studies assessing cancer vaccines, one expert explains what this may mean for patients in the future.

When given after surgery, Opdivo improved relapse-free survival compared to placebo in patients with stage 2B or 2C skin cancer, according to recent results from the CheckMate-76K clinical trial.

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.

Recent research has demonstrated the ability of immunotherapy combinations to target advanced melanoma.

Immunotherapy side effects are a different than those of chemotherapy and other cancer treatments. Patients should know when to seek emergency care and what to communicate to clinicians.

One oncologist highlighted the knowledge base of the immunotherapy and targeted therapy and how they interact with cancer cells.

Getting rid of the "blanket statement" and looking deeper into genetics may allow patients with cancer who are older than 60 years to become eligible for immunotherapy, highlighting the importance of further research on the topic.

Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.

BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.

First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.

The gut microbiome plays an important role in how patients may respond to cancer treatments, and researchers are learning more about ways to alter it to benefit treatment outcomes.

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.

Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.